HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Cyclarity reports data on removing toxic 7-ketocholesterol from atherosclerotic plaque

Louis Nervegna · May 23, 2026 · ♥ 7 reactions · 5 comments · original Facebook post
Plaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugs
AI summary & key facts

Quoted news that Cyclarity Therapeutics presented data on a small molecule designed to bind and remove 7-ketocholesterol, an oxidized cholesterol linked to plaque inflammation and instability. Details are limited to the company's announcement.

Quoted:

Selective Plaque Clearance

Cyclarity Therapeutics has presented new data supporting its small molecule approach to cardiovascular disease, targeting damaged atherosclerotic plaque directly. The therapy is designed to bind and remove 7-ketocholesterol, a toxic oxidized cholesterol linked to inflammation and plaque instability in arterial walls.

Link to full video on YouTube:

▶Video · YouTube · Longevity.TechnologyLongevity.Technology UNLOCKEDLongevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth...m.youtube.com

#reverseHD #7ketocholesterolHD #cyclaritytherapeuticsHD

Research cited

← newer: Obicetrapib improved Alzheimer's biomarkers, most in APOE4/4older: Even 'normal' vitamin B12 may be too low for older brains; a →